טוען...
Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions
BACKGROUND: This study was to investigate the efficacy and safety of anlotinib for elderly patients with previously treated extensive-stage small cell lung cancer (ES-SCLC) and the prognostic significance of common adverse reactions. PATIENTS AND METHODS: A total of 79 elderly patients (≥60 years) w...
שמור ב:
| הוצא לאור ב: | Cancer Manag Res |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7646458/ https://ncbi.nlm.nih.gov/pubmed/33173346 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S275624 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|